Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

Nesiritide (Natrecor) peptide icon, one bubble per amino acidNesiritide (Natrecor)32 residuesSPKMVQGSGCFGRKMDRISSSSGLGCKVLRRHEach bubble = one amino acid. Size = residue mass. Color = chemical class.

Nesiritide (Natrecor)

18 min half-life·Injection

Also known as: Natrecor, rhBNP, BNP-32

Seven thousand one hundred and forty-one patients enrolled in ASCEND-HF, and the result was a clear "cannot be recommended for routine use." Nesiritide (Natrecor) is a recombinant copy of human B-type natriuretic peptide, a 32-amino-acid hormone your ventricles release when they're overloaded. The FDA approved it in 2001 for acute decompensated heart failure, and it does lower pulmonary capillary wedge pressure fast. The problem: it never proved it saves lives. Clinical use dropped 64% after the 2005 mortality signal, and the drug has since been discontinued from the US market; FDA withdrew its approval in 2020. It remains a textbook example of hemodynamic improvement without clinical benefit.

What Is Nesiritide (Natrecor)?

Nesiritide (brand name Natrecor, CAS 124584-08-3) is a recombinant form of the 32-amino-acid human B-type natriuretic peptide. The ASCEND-HF trial [1] concluded it "cannot be recommended for routine use in the broad population of patients with acute heart failure," and that verdict effectively ended its clinical life. Your ventricular cardiomyocytes produce this same molecule when wall stress climbs too high. The synthetic version binds natriuretic peptide receptor-A, triggers cGMP production, and relaxes both arteries and veins. Hemodynamic effects start within 15 minutes of an IV bolus.

The early data looked good. The VMAC trial (2002)[2] showed nesiritide reduced pulmonary capillary wedge pressure better than IV nitroglycerin and improved dyspnea scores. Cardiologists prescribed it widely; peak-year revenue exceeded expectations. Then came the Sackner-Bernstein meta-analysis in 2005 [3], which flagged a 74% increased 30-day mortality signal (p=0.059). Prescriptions dropped 64% almost overnight.

ASCEND-HF settled the question in 2011. Across 7,141 patients with acute decompensated heart failure, nesiritide modestly improved dyspnea at 6 and 24 hours but missed the pre-specified significance threshold. Thirty-day mortality was 3.6% versus 4.0% for placebo; rehospitalization showed no difference either. The drug has since been pulled from the US market. It is not available for new clinical use from any legitimate source.

How Nesiritide (Natrecor) Works

Nesiritide is identical in sequence to the BNP your ventricular myocardium releases under volume overload. The target is natriuretic peptide receptor-A (NPR-A), also called guanylyl cyclase-A, found on vascular smooth muscle, endothelial cells, renal tubules, and adrenal tissue.

Binding activates the receptor's intracellular guanylyl cyclase domain. GTP converts to cyclic GMP; cGMP activates protein kinase G. PKG then dephosphorylates myosin light chains and lowers intracellular calcium in smooth muscle. The result is vasodilation in both arterial and venous beds, reducing preload and afterload simultaneously.

In the kidneys, cGMP signaling increases glomerular filtration and blocks sodium reabsorption in the collecting ducts. That produces natriuresis and diuresis. Nesiritide also suppresses the renin-angiotensin-aldosterone system and dials down sympathetic nervous system activity, adding to the hemodynamic relief.

Three clearance pathways handle elimination: NPR-C clearance receptors internalize and degrade it lysosomally; neprilysin (neutral endopeptidase) cleaves it proteolytically; and the kidneys filter it directly. The plasma half-life is just 18 minutes, but here's the catch. Blood pressure effects last roughly 2.2 hours on average. That pharmacodynamic tail is what makes hypotension management so tricky; stopping the infusion doesn't fix the problem quickly.

Nesiritide (Natrecor) Benefits

  • Nesiritide benefits center on rapid hemodynamic stabilization in acute decompensated heart failure, though the lack of mortality benefit limits its clinical value.
  • PCWP drops within 15 minutes of the IV bolus, faster than IV nitroglycerin in the VMAC trial (n=489)[2].
  • Balanced vasodilation hits both preload and afterload, a cleaner hemodynamic profile than pure arterial vasodilators.
  • Cardiac output improves without direct inotropic stimulation, avoiding the arrhythmia risk that comes with dobutamine or milrinone.
  • Natriuresis and diuresis kick in during infusion, helping relieve fluid overload through a mechanism distinct from loop diuretics.
  • Dyspnea improved modestly at 6 and 24 hours in ASCEND-HF (n=7,141), though it missed the pre-specified significance bar.
  • Right atrial pressure and systemic vascular resistance both decrease during infusion, improving the overall hemodynamic picture in volume-overloaded patients.

Nesiritide (Natrecor): Science vs Community Consensus

Science Only
Scientific Evidence
Strong
Based on 4 key studies·Research only

Nesiritide reduces PCWP and improves dyspnea in ADHF (VMAC, 2002).

Dosing studied: 2 mcg/kg IV bolus over 60 sec; then 0.01 mcg/kg/min continuous infusion (max 0.03 mcg/kg/min); up to 48-96 hours
Read the evidence (key study, limitations)

ASCEND-HF (2011, n=7,141) showed no mortality or rehospitalization benefit vs placebo; guideline conclusion: "cannot be recommended for routine use." Drug subsequently discontinued in the US; FDA withdrew approval effective June 15, 2020, not for safety or effectiveness reasons (86 FR 1516). 2005 Sackner-Bernstein meta-analysis flagged 74% increased 30-day mortality signal (p=0.059)[3], not confirmed in ASCEND-HF.

Key Study

ASCEND-HF (O'Connor et al., NEJM 2011, PMID 21732835)

Limitations

Modest dyspnea improvement at 6 and 24 hours missed pre-specified significance threshold. No survival benefit. PD half-life (~2.2 h for hypotension) substantially exceeds PK half-life (18 min), complicating hemodynamic management. Drug discontinued: no longer available for new use.

Community Experience
Weak
3.5/5
Based on ~0 Reddit mentions

No community or self-administration use exists.

Community dosing: N/A
Read the reports

Nesiritide is a hospital-only IV drug discontinued from the US market.

What users report (0)
    Common issues (0)
      Science-Only Evidence

      No community self-administration data exists. All evidence is from clinical trials and the FDA label. Drug is discontinued and was never available outside monitored hospital settings.

      Nesiritide (Natrecor) Dosage Guide

      FDA LabelNATRECOR (nesiritide) FDA Prescribing Information (2019)Source (opens in a new tab)
      LevelDose / InjectionFrequency
      Beginner2 mcg/kgIV bolus + 0.01 mcg/kg/min infusion
      Moderate2 mcg/kgIV bolus + 0.01 mcg/kg/min infusion
      Aggressive2 mcg/kgIV bolus + 0.03 mcg/kg/min infusion
      Note:

      Nesiritide is discontinued from the US market. This page exists for clinical reference, not practical sourcing guidance. You won't find it through any legitimate supply channel.

      When it was available, each 1.5 mg vial got reconstituted with 5 mL of diluent pulled from a 250 mL IV bag (D5W, normal saline, or 5% dextrose/0.2% NaCl). That gave 0.32 mg/mL in the vial. The entire contents then went back into the 250 mL bag for a final concentration of roughly 6 mcg/mL.

      For a 70 kg patient: the bolus is 2 mcg/kg = 140 mcg, which is about 23 mL of the 6 mcg/mL solution, given over 60 seconds. Maintenance runs at 0.01 mcg/kg/min = 0.7 mcg/min = 7 mL/hr on the infusion pump.

      The thing most residents miss: stopping the infusion doesn't stop the hypotension. Plan for 2+ hours of blood pressure monitoring after you turn it off. And never run it through the same line as heparin or furosemide; it precipitates.

      Cycling

      Nesiritide is used exclusively for acute treatment of decompensated heart failure in hospitalized settings, typically as a single continuous infusion lasting up to 48 hours. It is not cycled and is not intended for outpatient, intermittent, or scheduled repetitive use.

      Calculate your Nesiritide (Natrecor) dose
      Dosing tiers, timing, and cycle length

      Or use the universal Peptide Calculator for any peptide.

      Nesiritide (Natrecor) Protocols by Goal

      advancedFDA LabelSingle hospitalization event; infusion up to 48-96 hours. Not for repeated or scheduled use.
      IV Bolus
      Wk N/A: single event
      2 mcg/kg · Single bolus administered over 60 seconds · IV (dedicated port)
      Maintenance Infusion
      Wk N/A: up to 48-96 hours
      0.01 mcg/kg/min; may titrate up to 0.03 mcg/kg/min max · Continuous infusion; titrate no more than every 3 hours · IV continuous

      Expected: Rapid PCWP reduction within 15 minutes. Modest dyspnea improvement at 6-24 hours. No demonstrated mortality or rehospitalization benefit (ASCEND-HF).

      Monitor: Continuous BP monitoring required. Target systolic BP ≥90 mmHg. Serum creatinine and eGFR baseline and daily. PCWP monitoring if pulmonary artery catheter in place. Urine output to assess natriuresis.

      How to Inject Nesiritide (Natrecor)

      1. 1
        Step 1

        Confirm the patient has acute decompensated heart failure with dyspnea at rest or with minimal activity. This drug is hospital-only, requiring continuous hemodynamic monitoring.

      2. 2
        Step 2

        Pull 5 mL of diluent from a pre-filled 250 mL IV bag (D5W, 0.9% NaCl, or 5% dextrose/0.2% NaCl). Inject into the 1.5 mg nesiritide vial. Gently rock to dissolve. Do not shake. This gives 0.32 mg/mL.

      3. 3
        Step 3

        Withdraw the full reconstituted volume and inject it back into the 250 mL IV bag. Final concentration is approximately 6 mcg/mL.

      4. 4
        Calculate the bolus: 2 mcg/kg of body weight

        For a 70 kg patient, that is 140 mcg = 23.3 mL of the 6 mcg/mL solution. Administer over 60 seconds through a dedicated IV port.

      5. 5
        Step 5

        Immediately start the continuous infusion at 0.01 mcg/kg/min. For 70 kg at 6 mcg/mL, set the pump to 7 mL/hr.

      6. 6
        Step 6

        If response is inadequate, the rate may be increased up to 0.03 mcg/kg/min maximum. Do not uptitrate more often than every 3 hours. Each increase raises hypotension and renal risk.

      7. 7
        Monitor systolic blood pressure continuously

        If it drops below 90 mmHg, reduce or stop the infusion. Prepare IV fluid support if needed.

      8. 8
        Step 8

        Do not co-administer through the same IV line with heparin, furosemide, bumetanide, ethacrynic acid, enalaprilat, insulin, or hydralazine. Physical incompatibility causes precipitation. Use a dedicated IV port.

      9. 9
        Maximum infusion duration is 48 to 96 hours

        Check serum creatinine and eGFR daily. Monitor urine output hourly. Track electrolytes every 24 hours.

      10. 10
        Step 10

        After discontinuation, continue blood pressure monitoring for at least 2 hours. Hemodynamic effects outlast the 18-minute plasma half-life by a wide margin.

      Nesiritide (Natrecor) Stacking Protocols

      Works With

      Avoid

      Heparin (IV)

      Physical incompatibility: precipitate forms in same IV line. Use dedicated port.

      Do not combine
      Furosemide (IV)

      Physical incompatibility: do not co-administer via same IV line.

      Do not combine
      Bumetanide (IV)

      Physical incompatibility per the FDA label: do not co-administer via the same IV line.

      Do not combine
      Ethacrynic acid (IV)

      Physical incompatibility per the FDA label: do not co-administer via the same IV line.

      Do not combine
      Enalaprilat / Enalapril (IV)

      Physical incompatibility: also additive hypotensive risk. FDA label incompatibility.

      Do not combine
      Insulin (IV)

      Physical incompatibility via same IV catheter.

      Do not combine
      Hydralazine (IV)

      Physical incompatibility via same IV catheter.

      Do not combine

      Estimated Cost

      Brand Price
      DISCONTINUED: Natrecor (nesiritide) 1.5 mg lyophilized vials were ~$400–600/vial during US availability. Typical hospitalization course (1–2 vials per day × 2–3 days) ran $1,500–3,000 in drug costs alone.

      Pricing updated 2026-04-09

      Nesiritide (Natrecor) Side Effects

      Hypotension is the primary concern with nesiritide, and it's worse than the 18-minute plasma half-life would suggest. Symptomatic blood pressure drops occur in about 4% of patients at the recommended dose, but the hemodynamic effects persist for roughly 2.2 hours on average after stopping the infusion. Compare that to nitroglycerin, where hypotension resolves in about 0.7 hours. You can't quickly reverse nesiritide's vasodilatory effects by turning off the drip.

      The 2005 Sackner-Bernstein meta-analysis [3] raised a more alarming flag: a 74% increase in 30-day mortality risk (p=0.059) across pooled trial data. ASCEND-HF did not confirm this signal (3.6% vs 4.0%, not statistically different), but the concern reshaped clinical practice permanently.

      Renal function deterioration is the second major issue. Patients with severe heart failure who depend on the renin-angiotensin-aldosterone system for renal perfusion are most vulnerable. Raised serum creatinine and declining eGFR were observed particularly at infusion rates above 0.01 mcg/kg/min. The 2005 renal meta-analysis [3] first documented this pattern.

      Ventricular tachycardia occurred in approximately 3% of patients in clinical trials. Headache is the most common non-cardiovascular side effect. Nausea, vomiting, dizziness, anxiety, insomnia, abdominal pain, and back pain have all been reported.

      Allergic reactions and anaphylaxis are rare but documented. The drug binds to receptors throughout the vasculature; hypersensitivity can produce systemic effects rapidly.

      If systolic blood pressure drops below 90 mmHg, the infusion should be reduced or stopped. Because the hemodynamic effects outlast the drug's presence in blood, IV fluid support may be needed while waiting for recovery. Continuous blood pressure monitoring is required during and for at least two hours after discontinuation. Any rise in serum creatinine during treatment warrants immediate dose reduction or cessation.

      Common Issues & Solutions

      Hypotension persisting after infusion stop: PD duration (~2.2 h) vastly exceeds PK half-life (18 min): expect prolonged BP effects; do not assume rapid resolution on discontinuation; prepare IV fluid support if needed.

      Worsening renal function: reduce or stop infusion, especially if dose >0.01 mcg/kg/min; highest risk in patients dependent on RAAS for renal perfusion (severe HF with low cardiac output).

      IV line obstruction or precipitate: ensure nesiritide runs through a dedicated port: co-administration with heparin, furosemide, bumetanide, ethacrynic acid, enalaprilat, insulin, or hydralazine causes precipitation.

      Inadequate response at 0.01 mcg/kg/min: may titrate up to 0.03 mcg/kg/min, but never more frequently than every 3 hours. Each uptitration increases hypotension and renal risk.

      Drug not available: Nesiritide (Natrecor) has been discontinued from the US market: it cannot be sourced for new clinical use. Alternative: IV nitroglycerin (still available) for hemodynamic management of ADHF.

      Ask AI about this page

      Ask AI for a second opinion on Nesiritide (Natrecor) dosing and side effects

      Contraindications

      • Hypersensitivity to nesiritide or any component of the formulation
      • Cardiogenic shock or systolic blood pressure below 90 mmHg used as primary therapy
      • Significant valvular stenosis, restrictive or obstructive cardiomyopathy
      • Constrictive pericarditis or pericardial tamponade
      • Conditions where cardiac output is dependent on venous return
      • Pregnancy: FDA Category C; use only if potential benefit justifies risk to fetus
      • Breastfeeding: unknown whether nesiritide is excreted in human milk; use with caution in nursing mothers
      • Severe renal impairment (eGFR <30 mL/min) when renal perfusion is RAAS-dependent

      Drug Interactions

      • ACE inhibitors: increased risk of symptomatic hypotension when combined with nesiritide
      • IV heparin: physical incompatibility; do not co-administer through the same IV line
      • IV furosemide: physical incompatibility; do not co-administer through the same IV line
      • Insulin and hydralazine: physical incompatibility via same IV catheter
      • Other vasodilators and antihypertensives: additive hypotensive effects requiring close monitoring
      • IV bumetanide: physical incompatibility per the FDA label; do not co-administer through the same IV line
      • IV ethacrynate sodium: physical incompatibility per the FDA label; do not co-administer through the same IV line
      • IV enalaprilat: physical incompatibility per the FDA label; do not co-administer through the same IV line

      Product Quality

      Recommended Monitoring

      TestWhenTarget
      Blood pressure (systolic)Continuous during infusion; every 15 min for 1 hour post-bolus; every 30 min thereafter; 2+ hours post-discontinuationSystolic ≥90 mmHg: reduce or stop infusion if BP falls below threshold
      Serum creatinine / eGFRBaseline before initiation; every 24 hours during infusionNo established target; watch for rising creatinine or falling eGFR trend
      Pulmonary capillary wedge pressure (PCWP)If pulmonary artery catheter in place: baseline, 1 hour, and as clinically indicatedClinical reduction from elevated baseline (typically >18 mmHg at initiation)
      Urine output / fluid balanceHourly during infusion>0.5 mL/kg/hr indicates adequate hemodynamic response
      Serum electrolytes (Na, K)Baseline and every 24 hoursNot listed
      Blood pressure (systolic)

      Primary dose-limiting toxicity; hypotension can be prolonged due to PD half-life exceeding PK half-life

      Serum creatinine / eGFR

      Nesiritide can worsen renal function, particularly at doses >0.01 mcg/kg/min in RAAS-dependent patients

      Pulmonary capillary wedge pressure (PCWP)

      Primary hemodynamic endpoint; nesiritide approved for PCWP reduction in ADHF

      Urine output / fluid balance

      Natriuretic effect is a primary mechanism; adequate urine output confirms efficacy

      Serum electrolytes (Na, K)

      Natriuresis may cause electrolyte shifts; hypokalemia risk in combination with loop diuretics

      Nesiritide (Natrecor) Before and After

      0-15 minutes

      Onset of hemodynamic effects with reduction in PCWP and right atrial pressure following IV bolus

      15-60 minutes

      Significant decrease in systemic vascular resistance, reduction in dyspnea symptoms, and improved cardiac output

      1-3 hours

      Sustained hemodynamic improvement with peak vasodilatory and natriuretic effects during continuous infusion

      3-48 hours

      Maintained hemodynamic stabilization; continued monitoring for hypotension and renal function required

      Post-infusion

      Hemodynamic effects gradually resolve over approximately 60 minutes after discontinuation; systolic BP returns to baseline

      What to Expect

      0 to 15 minutes (Bolus onset): Hemodynamic effects begin almost immediately after the IV bolus. PCWP and right atrial pressure start falling within minutes. This is also the highest-risk window for acute hypotension, so blood pressure monitoring should already be running before the bolus goes in.

      15 to 60 minutes (Early infusion): Systemic vascular resistance drops measurably. Cardiac output increases without direct inotropic stimulation. Some patients report modest dyspnea improvement in this window. Headache and dizziness may appear as blood pressure adjusts.

      1 to 3 hours (Peak hemodynamic effect): Vasodilatory and natriuretic effects reach their maximum during continuous infusion. Urine output should be climbing if the drug is working. Symptomatic hypotension can persist or worsen even if the infusion rate hasn't changed; the pharmacodynamic curve keeps building beyond what the 18-minute plasma half-life would predict.

      3 to 48 hours (Maintenance): Hemodynamic stabilization holds as long as the infusion runs. Renal function monitoring becomes the priority. Creatinine may start rising, particularly at rates above 0.01 mcg/kg/min. Ventricular tachycardia occurs in roughly 3% of patients during this window.

      Post-infusion (Recovery): After stopping the drip, blood pressure effects take about 2.2 hours to resolve on average. That's far longer than the 18-minute elimination half-life. Keep monitoring. IV fluids should be ready if systolic pressure stays below 90 mmHg. Dyspnea relief may outlast the hemodynamic effects.

      Detailed Timeline: Science vs Community

      0–15 minutes
      Science

      Rapid reduction in PCWP and right atrial pressure following IV bolus; onset within minutes.

      Community

      N/A: hospital-monitored setting only; no community data.

      15–60 minutes
      Science

      Significant decrease in SVR; modest improvement in dyspnea symptoms; increased cardiac output without direct inotropic stimulation.

      Community

      N/A

      1–3 hours
      Science

      Maximal vasodilatory and natriuretic effects during continuous infusion; urine output increases.

      Community

      N/A

      3–48 hours
      Science

      Sustained hemodynamic stabilization; renal function monitoring critical: creatinine rise possible at doses >0.01 mcg/kg/min.

      Community

      N/A

      Post-infusion
      Science

      Hemodynamic effects resolve over ~2.2 hours after discontinuation (PD half-life); systolic BP returns to baseline. Dyspnea relief may persist.

      Community

      N/A

      Pharmacokinetics

      Half-Life
      18min
      Bioavailability
      100% (intravenous administration)
      Tmax
      Immediate (IV bolus)
      Data Confidence
      high

      Source: FDA label: mean terminal elimination half-life ~18 minutes

      Pharmacokinetics: Active Dose Over Time

      t½ = 18 minutes

      Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

      Molecular Profile

      Amino Acids
      32
      Sequence
      SPKMVQGSGCFGRKMDRISSSSGLGCKVLRRH
      HydrophobicPolarPositiveNegativeSpecialHow we generate these icons
      Identifiers
      CAS: 124584-08-3

      Who Should Consider Nesiritide (Natrecor)

      • Hospitalized patients with acute decompensated heart failure
      • Patients with dyspnea at rest or with minimal activity
      • Heart failure patients requiring preload and afterload reduction
      • Patients unresponsive to initial standard heart failure therapy
      • Adults with elevated pulmonary capillary wedge pressure

      Related Peptides

      What Changed for Nesiritide (Natrecor)

      1. Safety

        Corrected Oct 18, 2026: nesiritide's interaction list now names IV enalaprilat, incompatible in the same IV line, per the Natrecor label, section 2.4.

        Before: Heparin, furosemide, insulin, hydralazine, bumetanide and ethacrynate sodium listed; enalaprilat missing After: IV enalaprilat: physical incompatibility per the FDA label; do not co-administer through the same IV line

        What this does not mean: No new safety finding. The page already named enalaprilat in its FAQ, guide and stacking notes; the interaction list now matches the label.

        Source: Natrecor (nesiritide) prescribing information, section 2.4 (openFDA label record, SPL version 12, effective May 15, 2020) (opens in a new tab) · Saved copy

      2. Safety

        Corrected Oct 17, 2026: two unnamed nesiritide IV incompatibility notes now name bumetanide and ethacrynate sodium, per the Natrecor label, section 2.4.

        Before: Two notes read "Physical incompatibility", documented in the FDA label, without naming a drug After: IV bumetanide and IV ethacrynate sodium: physical incompatibility per the FDA label; do not co-administer through the same IV line

        What this does not mean: No new safety finding. Both notes already pointed to the FDA label; they now name the drugs it lists. Heparin, insulin, hydralazine and furosemide were already named.

        Source: Natrecor (nesiritide) prescribing information, section 2.4 (openFDA label record, SPL version 12, effective May 15, 2020) (opens in a new tab) · Saved copy

      3. Regulatory

        Corrected Oct 10, 2026: nesiritide's US status now records the Natrecor withdrawal (NDA 020920), effective Jun 15, 2020, per Federal Register 2020-10367.

        Before: No sourced US status record After: Not approved in the US: Natrecor NDA 020920 approval withdrawn June 15, 2020 (85 FR 28950), not for safety or effectiveness (86 FR 1516)

        What this does not mean: FDA found Natrecor was not withdrawn from sale for safety or effectiveness reasons (86 FR 1516). The trial data on this page are unchanged.

        Source: Federal Register 2020-10367 (85 FR 28950, May 14, 2020): Withdrawal of Approval of 16 New Drug Applications, including NDA 020920 Natrecor; approval withdrawn as of June 15, 2020 (opens in a new tab) · Saved copy

      4. Regulatory

        Corrected Oct 10, 2026: nesiritide's research stage is now discontinued, after the Jun 15, 2020 Natrecor withdrawal, per Federal Register 2020-10367.

        Before: Approved After: Discontinued

        What this does not mean: FDA found Natrecor was not withdrawn from sale for safety or effectiveness reasons (86 FR 1516). The trial data on this page are unchanged.

        Source: Federal Register 2020-10367 (85 FR 28950, May 14, 2020): Withdrawal of Approval of 16 New Drug Applications, including NDA 020920 Natrecor; approval withdrawn as of June 15, 2020 (opens in a new tab) · Saved copy

      5. Regulatory

        Corrected Oct 10, 2026: FDA withdrew approval of Natrecor (nesiritide, NDA 020920) effective Jun 15, 2020, per Federal Register 2020-10367.

        Before: FDA Approved After: Research (no FDA-approved product; the Natrecor approval was withdrawn as of June 15, 2020)

        What this does not mean: FDA found Natrecor was not withdrawn from sale for safety or effectiveness reasons (86 FR 1516). The trial data on this page are unchanged.

        Source: Federal Register 2020-10367 (85 FR 28950, May 14, 2020): Withdrawal of Approval of 16 New Drug Applications, including NDA 020920 Natrecor; approval withdrawn as of June 15, 2020 (opens in a new tab) · Saved copy

      6. Regulatory

        Corrected Oct 10, 2026: nesiritide's evidence label is now extensively studied, after the Jun 15, 2020 Natrecor withdrawal, per Federal Register 2020-10367.

        Before: FDA Approved After: Extensively Studied (VMAC; ASCEND-HF, n=7,141)

        What this does not mean: FDA found Natrecor was not withdrawn from sale for safety or effectiveness reasons (86 FR 1516). The trial data on this page are unchanged.

        Source: Federal Register 2020-10367 (85 FR 28950, May 14, 2020): Withdrawal of Approval of 16 New Drug Applications, including NDA 020920 Natrecor; approval withdrawn as of June 15, 2020 (opens in a new tab) · Saved copy

      Peptide Schedule Research TeamReviewed Apr 8, 20264 Citations

      References

      1. [1]Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF) (opens in a new tab)PubMed (opens in a new tab)PubMed
      2. [2]Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial (VMAC) (opens in a new tab)PubMed (opens in a new tab)PubMed
      3. [3]Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure (Circulation 2005) (opens in a new tab)PubMed (opens in a new tab)PubMed

      Related Tools

      Storage & Stability

      Before Reconstitution
      Store below 25°C (77°F). Do not freeze. Keep in outer carton to protect from light.
      After Reconstitution
      Stable for up to 24 hours at 2-25°C (36-77°F). Contains no antimicrobial preservative: use within 24 hours.
      Temperature
      2-25°C (36-77°F)

      Frequently Asked Questions

      No. Nesiritide (Natrecor) has been discontinued in the US. Clinical use dropped roughly 64% after the 2005 Sackner-Bernstein mortality signal and effectively died after ASCEND-HF in 2011 showed no benefit for mortality or rehospitalization. FDA withdrew approval of Natrecor (NDA 020920) effective June 15, 2020, at the request of the application holder (85 FR 28950). No FDA-approved nesiritide product exists today.

      The plasma half-life is 18 minutes, but the blood pressure effects last much longer: symptomatic hypotension averaged 2.2 hours vs 0.7 hours with nitroglycerin in trials. Stopping the infusion doesn't rapidly reverse the hemodynamic effects, so close BP monitoring is needed well after discontinuation.

      The NEJM 2011 paper concluded nesiritide "cannot be recommended for routine use in the broad population of patients with acute heart failure." There was a small dyspnea improvement at 6 and 24 hours, but it missed the pre-specified significance threshold. Thirty-day mortality (3.6% vs 4.0%) wasn't significantly different from placebo.

      Yes, particularly at doses exceeding 0.01 mcg/kg/min. Elevated creatinine and decreased eGFR were observed in patients with severe heart failure who depend on the RAAS system for renal perfusion. The 2005 renal meta-analysis (PMID 15781736) first flagged this concern.

      Physical incompatibility: these agents form precipitate or degrade when co-administered through the same line. Nesiritide needs a dedicated IV port. It's also incompatible with bumetanide, ethacrynic acid, enalaprilat, hydralazine, and insulin.